BACKGROUND AND PURPOSE: Hypertonic saline (3% NaCl) infusions can be used to treat acute neurologic hyponatremia (ANH) in critically ill patients with neurological and neurosurgical disorders such as subarachnoid hemorrhage. Adjustments in the rate of hypertonic saline infusions to treat ANH are needed to achieve a goal sodium range and are usually made on an empiric basis. To date, no data are available to determine how reliably such adjustments achieve stable, normal serum sodium concentrations or how often iatrogenic hypernatremia occurs during the course of treatment with hypertonic saline. METHODS: We have instituted a standardized sliding-scale hypertonic saline protocol to minimize patient-to-patient variability of hypertonic saline administration and to attempt to achieve safe rates of sodium correction and stable maintenance of serum sodium concentration with minimal overshoot. Here, we present a retrospective analysis of the performance characteristics of our standardized hypertonic saline protocol over a 1-year period, in 49 patients. RESULTS: The mean rate of initial sodium correction was 0.44 +/- 0.36 (mEq/l)/h. During the maintenance infusion phase, 84.3 +/- 17.8% of the time was spent in goal range (Na 136-145 mEq/l), 14.9 +/- 18.1% of the time was spent in mild undershoot (Na 130-135 mEq/l), and 0.7 +/- 3.1% of the time was spent in overshoot (Na >145 mEq/l). No adverse events attributable to infusion of hypertonic saline were encountered. CONCLUSION: Our hypertonic saline sliding-scale protocol for treatment of ANH can be used reliably and achieves normal sodium concentrations in a safe manner with minimal overshoot.
BACKGROUND AND PURPOSE:Hypertonicsaline (3% NaCl) infusions can be used to treat acute neurologic hyponatremia (ANH) in critically illpatients with neurological and neurosurgical disorders such as subarachnoid hemorrhage. Adjustments in the rate of hypertonicsaline infusions to treat ANH are needed to achieve a goal sodium range and are usually made on an empiric basis. To date, no data are available to determine how reliably such adjustments achieve stable, normal serum sodium concentrations or how often iatrogenic hypernatremia occurs during the course of treatment with hypertonicsaline. METHODS: We have instituted a standardized sliding-scale hypertonicsaline protocol to minimize patient-to-patient variability of hypertonicsaline administration and to attempt to achieve safe rates of sodium correction and stable maintenance of serum sodium concentration with minimal overshoot. Here, we present a retrospective analysis of the performance characteristics of our standardized hypertonicsaline protocol over a 1-year period, in 49 patients. RESULTS: The mean rate of initial sodium correction was 0.44 +/- 0.36 (mEq/l)/h. During the maintenance infusion phase, 84.3 +/- 17.8% of the time was spent in goal range (Na 136-145 mEq/l), 14.9 +/- 18.1% of the time was spent in mild undershoot (Na 130-135 mEq/l), and 0.7 +/- 3.1% of the time was spent in overshoot (Na >145 mEq/l). No adverse events attributable to infusion of hypertonicsaline were encountered. CONCLUSION: Our hypertonicsaline sliding-scale protocol for treatment of ANH can be used reliably and achieves normal sodium concentrations in a safe manner with minimal overshoot.
Authors: Sheila Singh; Desmond Bohn; Ana P C P Carlotti; Michael Cusimano; James T Rutka; Mitchell L Halperin Journal: Crit Care Med Date: 2002-11 Impact factor: 7.598
Authors: E Berendes; M Walter; P Cullen; T Prien; H Van Aken; J Horsthemke; M Schulte; K von Wild; R Scherer Journal: Lancet Date: 1997-01-25 Impact factor: 79.321
Authors: Philipp von Bismarck; Tobias Ankermann; Paul Eggert; Alexander Claviez; Michael J Fritsch; Martin F Krause Journal: Childs Nerv Syst Date: 2006-04-11 Impact factor: 1.475
Authors: M Oddo; J M Levine; S Frangos; E Carrera; E Maloney-Wilensky; J L Pascual; W A Kofke; S A Mayer; P D LeRoux Journal: J Neurol Neurosurg Psychiatry Date: 2009-03-16 Impact factor: 10.154
Authors: Mark Sherlock; Eoin O'Sullivan; Amar Agha; Lucy Ann Behan; Danny Rawluk; Paul Brennan; William Tormey; Christopher J Thompson Journal: Clin Endocrinol (Oxf) Date: 2006-03 Impact factor: 3.478
Authors: Muhammad Fahad Arshad; Ahmed Iqbal; James Weeks; Ines Fonseca; Alia Munir; William Bennet Journal: Endocr Connect Date: 2022-05-23 Impact factor: 3.221